PerkinElmer Highlights New Drug Discovery and Life Science Research Solutions at the Society

At the 17th annual Society for Biomolecular Sciences 2011 conference in Orlando, Florida, PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, will be showcasing several new drug discovery technologies and applications. The PerkinElmer exhibit, located at Booth 701, will include new products based on Alpha research and a novel panel of epigenetics-based detection reagents.

PerkinElmer's SBS offerings will include the Company's expanded epigenetic detection reagents exactly validated for drug discovery and life sciences technology for disease states including cancer, neurodegenerative and metabolic disorders, as then as applications for stem cells and immunology. Additionally, PerkinElmer will as well feature the EnSpire® Multimode Plate Reader with new optical label-free detection, the first and only benchtop detection platform to combine Corning® Epic® label-free innovation and traditional labeled assays to accurately identify and characterize potential new therapeutic targets. This combination of labeled and label-free detection technologies provides researchers with a more complete and insightful view of their cellular and biochemical interactions.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of roughly $1.7 billion in 2010, has about 6,200 employees serving clients in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.